Current Treatment Landscape of AQP4-IgG+ NMOSD and
Considerations on Relapse Rates
Michael Levy, MD, PhD, discusses how Aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) is…














